Opinion

Video

Dosing and Administration Considerations for Abiraterone Formulations

Author(s):

Gautam Jayram, MD,Christopher Pieczonka, MD

Panelists discuss how the dosing and administration of different abiraterone formulations vary, how food-related effects impact treatment efficacy, and strategies to manage these effects for optimal patient outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      • In your experience, what are the main differences in dosing and administration between the various formulations of abiraterone?
      • How do food-related effects influence the administration and efficacy of abiraterone treatments?
      • What strategies can be employed to manage these food-related effects to optimize patient outcomes?

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      The ADVANCED-2 trial, TARA-002
      The ADVANCED-2 trial, TARA-002
      Unmet needs in high risk NMIBC
      Unmet needs in high risk NMIBC
      2 experts in this video
      Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
      2 experts in this video
      The Current Landscape of ADT in Prostate Cancer
      1 expert is featured in this series.
      Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
      Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
      Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
      Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
      Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      1 expert is featured in this series.
      Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
      1 expert is featured in this series.
      Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
      Related Content
      Aquablation procedures for prostate cancer completed at ambulatory surgery center
      July 24th 2025

      Aquablation procedures for prostate cancer completed at ambulatory surgery center

      Hannah Clarke
      The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.
      Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
      July 15th 2025

      Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

      Amy M. Pearlman, MD
      Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
      Published: July 22nd 2025 | Updated: July 23rd 2025

      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

      Hannah Clarke
      The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
      June 30th 2025

      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

      Amy M. Pearlman, MD
      Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      July 18th 2025

      Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

      Hannah Clarke
      In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
      Urology in focus: Key moments from 2025
      July 18th 2025

      Urology in focus: Key moments from 2025

      Hannah Clarke
      Take a look back through some of the top stories from the first half of the year.
      © 2025 MJH Life Sciences

      All rights reserved.